Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a single shot stop clots? a new drug puts the idea to the test

NCT ID NCT03384966

Disease control Sponsor: Viatris Innovation GmbH Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 29, 2026 · Last updated Jul 30, 2026 · Updated 1 time

Summary

This trial investigates whether a single injection of selatogrel can quickly prevent platelets from clumping together in people with stable coronary artery disease. Researchers are also checking how fast the drug works, how long it lasts, and whether injecting it in the thigh or belly makes a difference. The study involves about 346 adults with stable coronary artery disease and compares selatogrel to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an injectable drug called selatogrel that prevents platelets from clumping together
What this could lead to
If it works, selatogrel could offer a fast-acting, easy-to-use option for preventing heart attacks in people with stable coronary artery disease.
What could go wrong
This is a Phase 2 trial, so the drug is still being tested for safety and effectiveness. It may not work as hoped or could cause side effects like bleeding.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

346 people

The number who actually took part.

Started

Jan 2018

Finished

Sep 2018

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Main Inclusion Criteria: 1. Signed informed consent prior to any study-mandated procedure. 2. Male and female subjects aged from 18-85 years, inclusive. 3. For women of childbearing potential: Negative urine pregnancy test at Visit 1 and at Visit 2 before randomization. 4. Stable Coronary artery disease (CAD) defined by the presence of any of the following conditions: 1. History of CAD with coronary artery stenosis on coronary angiogram ≥50%. 2. Previously documented myocardial infarction occurring more than 3 months prior to randomization. 5. Antiplatelet background therapy stable for at least 1 month prior to randomization. 6. Body weight ≥ 40.0 kg (88.2 lbs). Main Exclusion Criteria: 1. Acute coronary syndrome, percutaneous coronary intervention or any intervention for peripheral artery disease within 3 months prior to randomization. 2. Acute ischemic stroke or transient ischemic attack (TIA) within 3 months prior to randomization. 3. Active internal bleeding, or medical history of recent (\< 1 month) bleeding disorders or conditions associated with high risk of bleeding (e.g., clotting disturbances, gastrointestinal bleed, hemoptysis). 4. Hemoglobin ≤ 10 g/dL at screening. 5. Loss of at least 250 mL of blood within 3 months of screening. 6. Use of anticoagulants (oral, parenteral) or fibrinolytic therapy within 24 h prior to screening (Visit 1). 7. Known platelet disorders (e.g., thrombasthenia, thrombocytopenia, von Willebrand disease). 8. Pregnant or breastfeeding women.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Stable coronary artery disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Stable coronary artery disease

Contacts and locations

Locations

  • Aarhus University Hospital

    Aarhus, 8200, Denmark

  • East & North Hertfordshire NHS Trust - Lister Hospital

    Stevenage, SG14AB, United Kingdom

  • Florida Hospital Tampa - Pepin Heart Institute

    Tampa, Florida, 33613, United States

  • Freeman Hospital - Cardiothoracic Department

    Newcastle upon Tyne, NE7 7DN, United Kingdom

  • Indiana University School of Medicine - Krannert Institute of Cardiology

    Indianapolis, Indiana, 46202, United States

  • Inova Cardiology

    Lutherville, Maryland, 21093, United States

  • Inova Center for Thrombosis Research and Translational Medicine

    Falls Church, Virginia, 22042, United States

  • Institut de Cardiologie de Montréal

    Montreal, Quebec, H1T 1C8, Canada

  • Maastricht UMC

    Maastricht, 6229 HX, Netherlands

  • Mount Sinai Hospital (New York)

    New York, New York, 10029, United States

  • National Heart Centre Singapore

    Singapore, 169609, Singapore

  • NorthShore University

    Chicago, Illinois, 73104, United States

  • Rigshospitalet

    Copenhagen, 2100, Denmark

  • Sahlgrenska University Hospital

    Gothenburg, 40530, Sweden

  • Sheffield Teaching Hospitals

    Sheffield, S5 7AU, United Kingdom

  • St. Antonius Ziekenhuis

    Nieuwegein, 3435 CM, Netherlands

  • Universitats-Herzzentrum

    Bad Krozingen, 79189, Germany

  • University Medical Center Groningen

    Groningen, 9713 GZ, Netherlands

  • University of Florida (UF) Jacksonville

    Jacksonville, Florida, 32209, United States

  • Uppsala University Hospital

    Uppsala, 18288, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.